iShares 7-10 Year Treasury Bond ETF (IEF) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- -Sector
- $97.9952W High
- $93.1152W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track iShares 7-10 Year Treasury Bond ETF (IEF) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, iShares 7-10 Year Treasury Bond ETF has traded between a low of $93.11 and a high of $97.99, highlighting its annual price range. Buy and sell iShares 7-10 Year Treasury Bond ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Most Recent News
Global muscle stimulator market to reach $1.16B by 2035, driven by rising demand in pain management and rehab.
The global muscle stimulator market is projected to grow from $812 million in 2025 to $1.16 billion by 2035, at a CAGR of 3.6%. Growth is fueled by increasing use of neuromuscular electrical stimulation devices for pain management, sports rehabilitat...
Global livestock monitoring market to hit $10.3B by 2030, driven by AI and digital farming tech.
The global livestock monitoring market is expected to grow from $6.2 billion in 2025 to $10.3 billion by 2030, at a CAGR of 10.6%, fueled by the adoption of AI, IoT sensors, and wearable tech in precision farming. Europe leads with the largest market...
Atlas Healthcare Fund's 2020 Eli Lilly bet soared 246%, showcasing early clinical insight in healthcare investing.
Atlas Healthcare Fund, managed by VST Capital, invested in Eli Lilly at around $350 per share in 2020, well before its GLP-1 drug tirzepatide became a major success. The stock now trades above $1,200, reflecting a gain of over 246%. This early invest...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.